BMRN
BioMarin Pharmaceutical Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +6.3% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 1.42M | $84.45M | n/a | −2 |
| Q2 2026 | 135 | +4 | 146.70M | $8.39B | +11 | −8 |
| Q1 2026 | 135 | -4 | 142.18M | $8.03B | +5 | −10 |
| Q4 2025 | 138 | +3 | 154.93M | $9.20B | +4 | n/a |
| Q3 2025 | 23 | -1 | 108.93M | $5.90B | n/a | −2 |
| Q2 2025 | 22 | -2 | 113.78M | $6.25B | n/a | −2 |
| Q1 2025 | 21 | 0 | 70.58M | $4.99B | +1 | −1 |
| Q4 2024 | 21 | +1 | 67.83M | $4.46B | +1 | n/a |
| Q3 2024 | 19 | 0 | 57.19M | $4.02B | +2 | −2 |
| Q2 2024 | 19 | n/a | 53.80M | $4.43B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | PRIMECAP Management ✦ | 18.87M | +0.4% | $1.33B | 1.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Dodge & Cox ✦ | 13.90M | -0.2% | $976.91M | 0.6% | ▼ Trim | 2 | SEC ↗ |
| 3 | Viking Global Investors ✦ | 9.75M | +38.1% | $685.56M | 2.5% | ▲ Add | 2 | SEC ↗ |
| 4 | Norges Bank ✦ (passive) | 3.53M | -2.4% | $248.37M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 5 | Elliott Investment Management ✦ | 3.50M | 0.0% | $246.04M | 2.4% | Held | 2 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 3.26M | +1.9% | $228.63M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 7 | Citadel Advisors ✦ | 1.20M | +115.9% | $84.66M | 0.1% | ▲ Add | 2 | SEC ↗ ×2 |
| 8 | T. Rowe Price ✦ | 663.55K | -32.5% | $46.64M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 9 | Millennium Management ✦ | 642.68K | -42.5% | $45.17M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 598.50K | +980.9% | $42.07M | 0.1% | ▲ Add | 2 | SEC ↗ ×4 |
| 11 | Renaissance Technologies ✦ | 418.87K | +260.5% | $29.44M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Two Sigma Investments ✦ | 299.53K | -12.0% | $21.05M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 13 | Point72 Asset Management ✦ | 197.72K | New | $13.90M | 0.0% | New | 1 | SEC ↗ |
| 14 | D. E. Shaw & Co. ✦ | 163.35K | -39.1% | $11.48M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 15 | Bridgewater Associates ✦ | 142.31K | +306.8% | $10.00M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 16 | Gotham Asset Management ✦ | 23.39K | New | $1.64M | 0.0% | New | 1 | SEC ↗ |
| 17 | Fisher Asset Management ✦ | 13.55K | +0.9% | $952,148 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 18 | Wellington Management ✦ | 7.06K | +2.0% | $496,177 | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 19 | GAMCO Investors ✦ | 6.57K | +23.5% | $461,454 | 0.0% | ▲ Add | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $13.90M | 0.0% |
| Gotham Asset Management | $1.64M | 0.0% |
Exited
| Soros Fund Management | $12.85M | was 0.4% |
| Marshall Wace | $3.52M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 549 holders, 183.01M shares, $10.09B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 17.56K sh · $1.16M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology